Compare Abeona Therapeutics Inc (ABEO) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Boeing Co — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Boeing Co trades at $224.58 (market cap $182.63B). The key difference: Boeing Co is far larger — about 489.2× Abeona Therapeutics Inc's market cap, and Boeing Co pays a 0.03% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BA | |
|---|---|---|
Market Cap | $373.32M | $182.63B |
Sector | Health | Industrials |
52-Week High | $7.23 | $252.15 |
52-Week Low | $4.17 | $179.12 |
Enterprise Value | $228.22M | $208.94B |
Volume | — | 7,591,579 |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Boeing (BA) trades at $231.68, up 2.29% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $268.33. The company returned to profitability in 2025 with $2.24B net income on $89.46B revenue, though valuation ratios like P/E of 92.7 remain elevated. Recent news highlights defense contract wins and production expansion, including a new 737 assembly line.
Outlook: Boeing's recovery trajectory offers upside potential driven by operational improvements and strong backlog, but high debt, thin margins, and execution risks pose challenges. Analyst sentiment is predominantly bullish, yet investors should weigh valuation concerns against growth catalysts in the aerospace cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
